Simvastatin Effect on High-Sensitivity C-Reactive Protein in Type 2 Diabetes Mellitus

Cardiovascular disease (CVD) as a complication of type 2 diabetes mellitus (T2DM) is associated with chronic low-grade inflammation. Statin has an anti-inflammatory effect that is marked by decreasing inflammatory marker, such as high-sensitivity C-reactive protein (hsCRP). This study aims to evaluate the administration of simvastatin in influencing hsCRP level in patients with T2DM. A randomized control study involving subjects with T2DM which divided into two groups was conducted. Pre- and post-treatment measurements of lipid profile, HbA1c, hsCRP were performed in both groups. Triglyceride and HbA1c levels were significantly different between two groups (p=0.001, p=0.016, respectively). Only HbA1c was significantly associated with pre-treatment hsCRP level (p = 0,006). After three months, statin group showed significantly lower hsCRP level than that before treatment (p=0.002). Moreover, pre- and post-treatment differences of hsCRP level in both groups were also significant (0.41±0.26 vs -0.13±0.32, respectively, p=0.003).Simvastatin could reduce inflammation in T2DM patients that was marked by decreasing level of hsCRP.